Ancora Advisors LLC Boosts Position in Kenvue Inc. $KVUE

Key Points

• Ancora Advisors LLC increased its stake in Kenvue Inc. by 2.6%, owning a total of 806,342 shares valued at $19.34 million as of the latest SEC filing.
• Several hedge funds, including Vanguard Group and JPMorgan Chase, also modified their positions in Kenvue, reflecting a growing interest from institutional investors, with 97.64% of shares owned by this group.
• Kenvue's quarterly earnings report revealed an EPS of $0.29, slightly exceeding expectations, alongside a dividend increase to $0.2075 per share, contributing to a 4.0% annualized yield.

Ancora Advisors LLC grew its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 2.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 806,342 shares of the company's stock after acquiring an additional 20,272 shares during the period. Ancora Advisors LLC's holdings in Kenvue were worth $19,336,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Evergreen Wealth Solutions LLC grew its position in Kenvue by 2.6% in the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company's stock worth $402,000 after acquiring an additional 432 shares in the last quarter. Fulton Bank N.A. raised its position in Kenvue by 0.6% in the 1st quarter. Fulton Bank N.A. now owns 78,888 shares of the company's stock worth $1,892,000 after purchasing an additional 465 shares during the period. Scott & Selber Inc. raised its position in Kenvue by 0.4% in the 1st quarter. Scott & Selber Inc. now owns 106,621 shares of the company's stock worth $2,557,000 after purchasing an additional 475 shares during the period. Wealth Alliance LLC boosted its stake in shares of Kenvue by 1.6% during the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company's stock valued at $762,000 after purchasing an additional 486 shares during the period. Finally, Everett Harris & Co. CA boosted its stake in shares of Kenvue by 1.4% during the first quarter. Everett Harris & Co. CA now owns 36,971 shares of the company's stock valued at $887,000 after purchasing an additional 500 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on KVUE. Citigroup dropped their price target on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. Canaccord Genuity Group reduced their price objective on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Bank of America reduced their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. Zacks Research raised shares of Kenvue to a "strong sell" rating in a research report on Monday, August 11th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $24.38.

Kenvue Stock Down 9.3%

Shares of NYSE:KVUE traded down $1.91 during midday trading on Friday, reaching $18.64. The company's stock had a trading volume of 135,326,130 shares, compared to its average volume of 13,801,933. The firm has a 50 day moving average of $21.37 and a 200-day moving average of $22.38. The firm has a market capitalization of $35.76 billion, a P/E ratio of 25.18, a PEG ratio of 2.67 and a beta of 0.83. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.15 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company's revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.5%. The ex-dividend date was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio is 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.